Jean-Michel Métry was born in Sion, Switzerland in 1955, was educated in local schools, and did his pre-doctoral education and research at the Swiss Federal Institute of Technology (ETH) in Zürich, under the direction of the late Professor Max Anliker. Dr Métry's first job was at 3-M Corporation, on cochlear implants.
In 1988, he joined California-based APREX Corporation as Director of APREX's European division, providing MEMS® monitors to European clinical researchers. When APREX was reorganized and sold to Apria Healthcare Corporation in the mid-1990's, Dr Métry and Dr John Urquhart, co-founder of APREX, created AARDEX Ltd. in Sion, Switzerland, to provide electronic monitors of prescription drug use in ambulatory medical care to the European clinical research marketplace.
In the late 1990's, AARDEX acquired the assets of APREX from Apria, and Dr Métry became CEO of AARDEX Ltd., located in Sion, Switzerland In 2002, Dr Métry and Prof. Urs Meyer, Professor of Pharmacology at University of Basel, published the book entitled «Drug Regimen Compliance: Issues in Clinical Trials and Patient Management» (John Wiley & Sons, Chichester, UK). Dr. Métry had a special interest in patient adherence during phase IV studies, as new, orally-administered drugs came into wide usage. The results of these studies played a leading role in bringing wide attention to objective data on ambulatory patients' often poor adherence to prescribed medicines in all modes of ambulatory care, irrespective of disease severity or prognosis, plus recognition that variable adherence is the leading source of variance in patients' responses to prescribed, orally-administered medicines.
Dr Métry's untimely death in 2009 ended his successful career as a scientist, biomedical engineer, and entrepreneur.